Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multi-center, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Patients
NCT05278663 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Multi-center, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Patients
- Lead sponsor
- Eisai Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- April 14, 2022
- Completion date
- September 4, 2023
- Enrollment
- 26 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.